Alphamab Oncology

Alphamab Oncology (9966.HK), headquartered in Suzhou, China, is a leading clinical-stage biopharmaceutical company deeply dedicated to the discovery, development, manufacturing, and commercialization of next-generation cancer therapeutics. Founded in 2008 by Dr. Ting Xu, the company operates with a rigorous mission to address significant unmet medical needs in oncology by engineering biologics that offer greater precision, lower toxicity, and superior efficacy. Through its fully integrated proprietary platforms in protein engineering and bispecifics, Alphamab Oncology aims to deliver world-class, China-innovated cancer therapies that fundamentally transform patient survival and quality of life on a global scale.

The company fundamentally disrupted the immuno-oncology landscape with the launch of its flagship product, ENWEIDA® (Envafolimab), which made history as the world’s first subcutaneously injected PD-L1 inhibitor. Beyond its commercialized portfolio, Alphamab is aggressively advancing a massive clinical pipeline anchored by highly specialized bispecific antibodies and advanced Antibody-Drug Conjugates (ADCs). Its lead bispecific asset, KN026 (an anti-HER2 antibody), is currently navigating pivotal Phase III trials for gastric and breast cancers and has already received Breakthrough Therapy Designation from both U.S. and Chinese regulators. Furthermore, the company leverages its proprietary site-specific glycan conjugation technology to develop highly sophisticated dual-target ADCs—such as the first-in-class TROP2/HER3 bispecific ADC JSKN016—designed to overcome resistance to traditional chemotherapies and targeted treatments.

Currently guided by Founder, Chairman, and CEO Dr. Ting Xu, alongside Chief Operating Officer Yang Liu, Alphamab Oncology is navigating a period of highly accelerated clinical execution. Moving through the first half of 2026, the company continues to demonstrate robust operational momentum following a resilient 2025 where it recorded RMB 566.24 million in total revenue. In April 2026, Alphamab announced a historic breakthrough when its Phase III trial for KN026 as a neoadjuvant treatment for breast cancer successfully met its primary endpoints. This momentum is set to be further highlighted at the prestigious 2026 ASCO Annual Meeting, where the company will present highly anticipated clinical data on JSKN016 in treating historically difficult HER2-negative breast cancers, cementing its status as an elite pioneer in the next generation of precision oncology.